Home The Word Brain	My Amedeo FAQ Privacy About
	2049 Chinese The 20K Word Road to Mandarin Proficiency By B. S. Kamps et al.

Leukemia

Free Subscription 25.11.2024 4 Am J Hematol 3 Ann Hematol 1 Biochem Biophys Res Commun 5 Blood 1 Bone Marrow Transplant 14 Br J Haematol 1 Int J Hematol 1 J Virol 2 Leuk Res 4 Leukemia 1 PLoS Comput Biol

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

Am J Hematol

1. ROY MOULIK N, Keerthivasagam S, Chatterjee G, Agiwale J, et al
   Treatment-Free Remissions in Children With Chronic Myeloid Leukemia (CML): A Prospective Study From the Tata Memorial Hospital (TMH) Pediatric CML (pCML) Cohort.
   Am J Hematol. 2024 Nov 20. doi: 10.1002/ajh.27528.
   PubMed         Abstract available
   
   
2. KONUMA T, Kameda K, Morita K, Kondo T, et al
   Different impacts of granulocyte colony-stimulating factor administration on allogeneic hematopoietic cell transplant outcomes for adult acute myeloid leukemia according to graft type.
   Am J Hematol. 2024 Nov 20. doi: 10.1002/ajh.27521.
   PubMed         Abstract available
   
   
3. SCHMALTER AK, Labopin M, Versluis J, Gallego Hernanz MP, et al
   The role of allogeneic stem cell transplantation in acute myeloid leukemia with translocation t(8;16)(p11;p13).
   Am J Hematol. 2024 Nov 18. doi: 10.1002/ajh.27496.
   PubMed         Abstract available
   
   
4. LIU H, Xu H, Chi P, Feng Z, et al
   A prophylactic tyrosine kinase inhibitor strategy based on measurable residual disease pre-transplantation for Ph(+) acute lymphoblastic leukemia undergoing allogeneic hematopoietic stem cell transplantation: A prospective multicenter cohort study.
   Am J Hematol. 2024 Nov 16. doi: 10.1002/ajh.27516.
   PubMed         Abstract available
   
   

   
   Ann Hematol

5. FLEISCHMANN M, Jentzsch M, Brioli A, Eisele F, et al
   Correction to: Azacitidine in combination with shortened venetoclax treatment cycles in patients with acute myeloid leukemia.
   Ann Hematol. 2024 Nov 20. doi: 10.1007/s00277-024-06095.
   PubMed        
   
   
6. BLANKSTEIN AR, Choi N, Mozessohn L, Sanford D, et al
   Supportive care strategies in myelodysplastic syndromes and acute myeloid leukemia in older adults: a national survey of Canadian hematologists.
   Ann Hematol. 2024 Nov 20. doi: 10.1007/s00277-024-06085.
   PubMed         Abstract available
   
   
7. MIZUNO S, Hosoi H, Takami A, Kawata T, et al
   Reappraising the prognostic relevance of cytogenetic risk in patients with acute myeloid leukemia undergoing allogeneic hematopoietic cell transplantation.
   Ann Hematol. 2024 Nov 19. doi: 10.1007/s00277-024-06094.
   PubMed         Abstract available
   
   

   
   Biochem Biophys Res Commun

8. SHARIPOV RR, Surin AM, Silonov SA, Smirnov EY, et al
   Promyelocytic leukemia protein (PML) knockout increases mitochondrial Ca(2+) uptake in HeLa cells.
   Biochem Biophys Res Commun. 2024;739:150990.
   PubMed         Abstract available
   
   

   
   Blood

9. DOHNER H, Pratz KW, DiNardo CD, Wei AH, et al
   Genetic risk stratification and outcomes among treatment-naive patients with AML treated with venetoclax and azacitidine.
   Blood. 2024;144:2211-2222.
   PubMed         Abstract available
   
   
10. DOHNER H, DiNardo CD, Appelbaum FR, Craddock C, et al
    Genetic risk classification for adults with AML receiving less-intensive therapies: the 2024 ELN recommendations.
    Blood. 2024;144:2169-2173.
    PubMed         Abstract available
    
    
11. LU P, Zhang X, Yang J, Li J, et al
    Nanobody-based Naturally Selected CD7-Targeted CAR-T Therapy for Acute Myeloid Leukemia.
    Blood. 2024 Nov 19:blood.2024024861. doi: 10.1182/blood.2024024861.
    PubMed         Abstract available
    
    
12. NAIR MS, Silbert SK, Rejeski K, Wilson KA, et al
    Development of ALL-Hematotox (ALL-HT): Predicting post CAR T-cell hematotoxicity in B-cell acute lymphoblastic leukemia.
    Blood. 2024 Nov 19:blood.2024025910. doi: 10.1182/blood.2024025910.
    PubMed         Abstract available
    
    
13. MA J, Wang Z, Mintzlaff D, Zhang H, et al
    Bivalent CD47 Immunotoxin for Targeted Therapy of T-Cell Acute Lymphoblastic Leukemia.
    Blood. 2024 Nov 19:blood.2024025277. doi: 10.1182/blood.2024025277.
    PubMed         Abstract available
    
    

    
    Bone Marrow Transplant

14. MOLINOS-QUINTANA A, Martinez-Cibrian N, Alonso-Saladrigues A, Galan-Gomez V, et al
    Successful allogeneic CD34(+) hematopoietic stem cell boost for prolonged cytopenias following CAR T-cell therapy in B-cell acute lymphoblastic leukemia. On behalf of the Spanish Group for Hematopoietic Transplantation and Cellular Therapy (GETH-TC).
    Bone Marrow Transplant. 2024 Nov 17. doi: 10.1038/s41409-024-02473.
    PubMed        
    
    

    
    Br J Haematol

15. WEINBERGEROVA B, Mayer J, Kabut T, Sperr WR, et al
    Fungal infection frequency in newly diagnosed acute myeloid leukaemia patients treated with venetoclax plus azacitidine with or without antifungal prophylaxis.
    Br J Haematol. 2024;205:1746-1750.
    PubMed         Abstract available
    
    
16. BARDINI M, Fazio G, Abascal LC, Meyer C, et al
    Prenatal origin of NUTM1 gene rearrangement in infant B-cell precursor acute lymphoblastic leukaemia.
    Br J Haematol. 2024;205:1883-1888.
    PubMed         Abstract available
    
    
17. ZHU Q, Nambiar R, Schultz E, Gao X, et al
    Genome-wide study identifies novel genes associated with bone toxicities in children with acute lymphoblastic leukaemia.
    Br J Haematol. 2024;205:1889-1898.
    PubMed         Abstract available
    
    
18. XU N, Dao FT, Shi ZY, Sun K, et al
    WT1 together with RUNX1::RUNX1T1 targets DUSP6 to dampen ERK activity in acute myeloid leukaemia.
    Br J Haematol. 2024;205:1848-1859.
    PubMed         Abstract available
    
    
19. YANG YT, Yao CY, Kao CJ, Chiu PJ, et al
    Clinical relevance of NFYA splice variants in patients with acute myeloid leukaemia undergoing intensive chemotherapy.
    Br J Haematol. 2024;205:1751-1764.
    PubMed         Abstract available
    
    
20. SPECTOR LG, de Smith AJ
    Backtracking childhood leukaemia to birth: A battle of addition.
    Br J Haematol. 2024;205:1670-1671.
    PubMed         Abstract available
    
    
21. CICCONI L, Bisegna M, Gurnari C, Fanciullo D, et al
    Leucocytosis during induction therapy with all-trans-retinoic acid and arsenic trioxide in acute promyelocytic leukaemia predicts differentiation syndrome and treatment-related complications.
    Br J Haematol. 2024;205:1727-1733.
    PubMed         Abstract available
    
    
22. ARIFFIN H
    Incorrigible inflammation.
    Br J Haematol. 2024;205:1679-1680.
    PubMed         Abstract available
    
    
23. MAILLET F, Galimard JE, Borie R, Lainey E, et al
    Haematological features of telomere biology disorders diagnosed in adulthood: A French nationwide study of 127 patients.
    Br J Haematol. 2024;205:1835-1847.
    PubMed         Abstract available
    
    
24. YANADA M
    Leucocytosis during all-trans retinoic acid and arsenic trioxide treatment in acute promyelocytic leukaemia.
    Br J Haematol. 2024;205:1672-1673.
    PubMed         Abstract available
    
    
25. PHILIP C, Selvarajan S, Nayak L, Jain H, et al
    Impact of the COVID-19 pandemic on treatment of patients with acute myeloid leukaemia in India.
    Br J Haematol. 2024;205:2058-2062.
    PubMed         Abstract available
    
    
26. GEISSLER K, Koristek Z, Del Castillo TB, Novak J, et al
    Oral decitabine/cedazuridine versus intravenous decitabine for acute myeloid leukaemia: A randomised, crossover, registration, pharmacokinetics study.
    Br J Haematol. 2024;205:1734-1745.
    PubMed         Abstract available
    
    
27. BOULIGNY IM, DiNardo CD
    Oral decitabine-cedazuridine in acute myeloid leukaemia.
    Br J Haematol. 2024;205:1674-1676.
    PubMed         Abstract available
    
    
28. LV M, Yan CH, Ma R, He Y, et al
    Mega-dose decitabine conditioning and prophylactic donor lymphocyte infusion for patients with relapsed/refractory AML with active disease at the time of allogeneic haematopoietic cell transplantation: A multicenter prospective phase II study.
    Br J Haematol. 2024;205:1910-1920.
    PubMed         Abstract available
    
    

    
    Int J Hematol

29. ISHII Y, Fujisawa S, Miyazaki T, Nakajima Y, et al
    Real-world toxicity and efficacy of asciminib in heavily pretreated patients with chronic myeloid leukemia.
    Int J Hematol. 2024 Nov 19. doi: 10.1007/s12185-024-03873.
    PubMed         Abstract available
    
    

    
    J Virol

30. ZHOU J, Zhou D, Zhang Q, Zhang X, et al
    DCLK1 mediated cooperative acceleration of EMT by avian leukosis virus subgroup J and Marek's disease virus via the Wnt/beta-catenin pathway promotes tumor metastasis.
    J Virol. 2024;98:e0111224.
    PubMed         Abstract available
    
    

    
    Leuk Res

31. QIAN S, Gong J, Shen X, Chen M, et al
    Causal role of genetically predicted 731 immune cell phenotypes in chronic lymphatic leukemia: A bidirectional Mendelian randomization study.
    Leuk Res. 2024;148:107621.
    PubMed         Abstract available
    
    
32. KIM JY, Vijayakumar KA, Cho GW
    Exploring the impact of methylation aging on acute myeloid leukemia: Insights from the aging clock.
    Leuk Res. 2024;148:107620.
    PubMed         Abstract available
    
    

    
    Leukemia

33. HEGDE M, Ahmad MH, Mulet Lazaro R, Sugita M, et al
    The co-receptor Neuropilin-1 enhances proliferation in inv(16) acute myeloid leukemia via VEGF signaling.
    Leukemia. 2024 Nov 21. doi: 10.1038/s41375-024-02471.
    PubMed         Abstract available
    
    
34. KAWASHIMA N, Gurnari C, Bravo-Perez C, Kubota Y, et al
    Clonal hematopoiesis in large granular lymphocytic leukemia.
    Leukemia. 2024 Nov 21. doi: 10.1038/s41375-024-02460.
    PubMed         Abstract available
    
    
35. DALTVEIT DS, Morgan E, Colombet M, Steliarova-Foucher E, et al
    Global patterns of leukemia by subtype, age, and sex in 185 countries in 2022.
    Leukemia. 2024 Nov 20. doi: 10.1038/s41375-024-02452.
    PubMed         Abstract available
    
    
36. KRISHNAMOORTHY V, Daly J, Kim J, Piatnitca L, et al
    The glycosyltransferase ST3GAL4 drives immune evasion in acute myeloid leukemia by synthesizing ligands for the glyco-immune checkpoint receptor Siglec-9.
    Leukemia. 2024 Nov 17. doi: 10.1038/s41375-024-02454.
    PubMed         Abstract available
    
    

    
    PLoS Comput Biol

37. ROADNIGHT SHEEHAN J, de Wijn AS, Freire TS, Friedman R, et al
    Beyond IC50-A computational dynamic model of drug resistance in enzyme inhibition treatment.
    PLoS Comput Biol. 2024;20:e1012570.
    PubMed         Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Leukemia is free of charge.